Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Phase 2

Completed

Conditions: Carcinoma

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Erlotinib
Other: Treatment determined by physician
Drug: Bevacizumab

First Posted Date: 2008-08-18

Last Posted Date: 2016-08-17

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 289

Registration Number: NCT00737243

Locations: 🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸
Wellstar Cancer Research, Marietta, Georgia, United States
🇺🇸
Integrated Community Oncology Network, Jacksonville, Florida, United States

and more 17 locations

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Ramucirumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-08-15

Last Posted Date: 2014-12-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT00735696

Locations: 🇬🇧
ImClone Investigational Site, London, United Kingdom

Sutent + Taxol for Advanced Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Sunitinib malate
Drug: Paclitaxel

First Posted Date: 2008-08-08

Last Posted Date: 2017-03-16

Lead Sponsor: Hoosier Cancer Research Network

Target Recruit Count: 28

Registration Number: NCT00730353

Locations: 🇺🇸
Ireland Cancer Center - University Hospitals of Cleveland, Cleveland, Ohio, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States

and more 12 locations

Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: carboplatin
Drug: hydroxychloroquine
Drug: paclitaxel

First Posted Date: 2008-08-06

Last Posted Date: 2017-05-23

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Target Recruit Count: 8

Registration Number: NCT00728845

Locations: 🇺🇸
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2008-07-29

Last Posted Date: 2014-03-07

Lead Sponsor: University of Chicago

Target Recruit Count: 26

Registration Number: NCT00724386

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: ABT-869
Drug: Placebo for ABT-869
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-07-16

Last Posted Date: 2013-04-29

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 145

Registration Number: NCT00716534

Locations: 🇺🇸
Site Reference ID/Investigator# 13101, Philadelphia, Pennsylvania, United States
🇺🇸
Site Reference ID/Investigator# 24122, Philadelphia, Pennsylvania, United States
🇧🇷
Site Reference ID/Investigator# 22684, Santo Andre, Brazil

and more 34 locations

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: AZD2281
Drug: Paclitaxel

First Posted Date: 2008-07-01

Last Posted Date: 2018-03-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 19

Registration Number: NCT00707707

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cavity Cancer
Ovarian Cancer

Interventions: Drug: cisplatin
Drug: paclitaxel
Drug: pemetrexed disodium
Other: biologic sample preservation procedure

First Posted Date: 2008-06-20

Last Posted Date: 2016-01-01

Lead Sponsor: University of Arizona

Target Recruit Count: 15

Registration Number: NCT00702299

Locations: 🇺🇸
Arizona Oncology - Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Carboplatin
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2008-06-05

Last Posted Date: 2016-09-22

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 46

Registration Number: NCT00691379

Locations: 🇬🇷
University General Hospital of Alexandroupolis, Alexandroupolis, Greece
🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

and more 8 locations

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

Phase 2

Completed

Conditions: Uterine Carcinosarcoma

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: BSI-201 (Iniparib)

First Posted Date: 2008-06-02

Last Posted Date: 2012-08-07

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT00687687

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy